Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Kaltura Inc (KLTR) Price & Performance

Davita IncTrade
Kaltura IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Kaltura Inc — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while Kaltura Inc trades at $1.32 (market cap $199.08M). The key difference: Davita Inc is far larger — about 56.7× Kaltura Inc's market cap, and Davita Inc is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Kaltura Inc for 21 Days on average.

DVAKLTR
Market Cap
$11.29B$199.08M
Volume
582,204175,927
Sector
HealthTechnology
52-Week High
$240.96$1.89
52-Week Low
$103.87$1.08
Typical Hold Time
114 Days21 Days
Enterprise Value
$24.01B$211.29M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.

Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.

Kaltura Inc

KLTR trades at $1.32, down 0.75% on the day, with bearish technical signals from moving averages. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though it remains unprofitable with negative ROE. Recent analyst coverage leans positive with 44% buy ratings, supported by multiple industry awards and AI platform deployments in 2026.

The outlook remains speculative given persistent losses and high valuation ratios, but growing AI integration and award recognition provide catalysts. Key risks include cash burn, competitive pressure, and execution challenges in achieving profitability. Wall Street sentiment is cautiously optimistic despite technical weakness.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
100% Buy0% Sell
Avg holding period · 114 Days
KLTR
0% Buy100% Sell
Avg holding period · 21 Days

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About Kaltura Inc

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)

Read more on KLTR →